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We read with great interest the Special Series entitled ‘Novel Therapeutic and 
Diagnostic Advances in Bone and Soft Tissue Sarcomas.’ These articles provide a 
comprehensive insight into current knowledge and evolving research in this 
heterogeneous group of tumors.  Although relevant diagnostic and therapeutic aspects 
of patient care are considered, there is almost no reference to the patient perspective of 
these advances. Most authors acknowledge the need for individualized care, with respect 
to clinical, genetic and molecular factors, however only Gounder et al refer to health-
related quality of life (HRQoL) measures as potentially meaningful clinical endpoints in 
locally advanced connective tissue tumors.  
Historically, evaluation of oncological treatments has focused on objective outcomes 
such as radiological response, progression-free and overall survival, and healthcare-
provider perspective of treatment-related toxicities. More recently, increasing attention 
has been given to patient reported outcomes (PROs), defined as ‘any report of the status 
of a patient’s health condition that comes directly from the patient, without 
interpretation of the patient’s response by a clinician or anyone else,’ in order to 
evaluate treatment efficacy(www.fda.gov). PROs include a range of outcomes such as 
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symptoms, functioning and HRQoL.  HRQoL is the most widely used PRO and is a 
multidimensional concept that includes the patient’s perception of the impact of the 
disease and its treatment on physical, psychological and social functioning.1 
Incorporating PROs into clinical practice can facilitate communication, improve 
symptom control and patient satisfaction and reduce hospital admissions.2 A recent 
study in patients with metastatic solid tumors showed that routine PRO monitoring and 
immediate response to adverse events led to a five month survival benefit compared 
with standard care3: more than most new drugs for metastatic cancers approved by the 
FDA in 2016(www.fda.gov).  
Data on HRQoL in sarcoma patients are limited, however many patients experience a 
substantial burden of physical and psychological symptoms, with an adverse impact on 
HRQoL.4 Integration of HRQoL with traditional measures of therapeutic response will 
provide a more comprehensive assessment of the efficacy and toxicity of novel 
therapies for sarcoma patients.5 Symptomatic toxicities are frequently underreported 
by clinicians, therefore PROs are a vital component of symptom detection, monitoring 
and early intervention.6 Precise assessments of how patients feel and function offer 
important additional information to evaluate the risks and benefits of treatments.1 
Patient experience is a key aspect of drug development, and survival alone is inadequate 
to determine net clinical benefit.7  Although some novel treatments have been approved 
for sarcomas over the last few decades, detailed data on short- and long-term side-
effects and HRQoL are scarce.4  The PALETTE study of pazopanib versus placebo, as 
second-line or greater treatment for advanced soft tissue sarcomas, is one of the few 
sarcoma trials which reported HRQoL as an exploratory endpoint.8 Pazopanib improved 
progression-free survival without relevant deterioration in HRQoL compared with 
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placebo.8 This demonstrates that combining HRQoL with clinical data can show overall 
clinical treatment benefit.  
One of the biggest challenges in sarcoma is how to assess HRQoL in this heterogeneous 
patient group. Previous studies have predominately used generic HRQoL instruments 
(EORTC-QLQ-C30, SF36, FACT-G), however these tools do not efficiently capture the 
unique experiences of sarcoma patients (e.g. disease-localization, treatment-specific 
symptoms) and thus lack content validity.   Traditionally inadequate content coverage 
has been addressed using a tumor-specific questionnaire that captures all disease-
specific HRQoL issues, in conjunction with generic HRQoL measures. Given the 
heterogeneity of sarcomas including patient age, histological subtype, physiological 
locations, disease stage and rapidly changing treatment landscape, associated with 
variable mechanisms of action and toxicity profiles, it may be challenging to develop 
one sarcoma-specific questionnaire that meets the needs of clinical practice, academia, 
and industry. Standardized, so called "static" questionnaires consisting of a fixed set of 
items may not be relevant for every sarcoma patient and may miss important patient-
reported adverse events. Consequently, a more flexible approach is needed to assess the 
impact of treatments, provide optimal supportive care and ultimately translate into 
meaningful outcomes for sarcoma patients.9 One option is to combine standardized PRO 
questionnaires with validated items from item libraries (e.g. PROMIS, EORTC), to ensure 
adequate assessment of specific treatments and their effects on common health 
problems.9  
In this era of personalized medicine, the principal focus has been on clinical and tumor 
characteristics without addressing individual patient perspective. If we really want to 
make a difference, truly provide personalized care and run trials that are attractive to 
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patients, we should routinely involve patients in trial design and integrate HRQoL 
assessments into clinical practice and research.10 This will enable provision of a more 
holistic approach to the overall management of patients.  
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